Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccination for glaucoma: dream or reality?

Michal Schwartz1

  • 1Department of Neurobiology, The Weizmann Institute of Science, 76100 Rehovot, Israel.

Brain Research Bulletin
|March 24, 2004
PubMed
Summary

Researchers explored using Cop-1 vaccination to harness the immune system for neuroprotection in glaucoma. This approach, termed "protective autoimmunity," showed significant recovery in damaged optic nerves in rat models.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer's disease: a phase 1b, randomized, double-blind trial.

Nature medicine·2026
Same author

Disruption of the brain-spleen axis impairs monocyte-microglia communication and accelerates disease progression in a mouse model of amyloidosis.

Nature communications·2026
Same author

Parsing the functions of immediate-early proteins in the lytic-latent balance of HCMV infection.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Treating the immune system to repair the brain.

Science translational medicine·2026
Same author

Author Correction: Viral entry shapes HCMV latency establishment.

Nature communications·2026
Same author

Evolving brain-immunity: From Ramón y Cajal's mysterious butterflies to a garden sustained by immune cells as their nectar.

Neuron·2026

Area of Science:

  • Neuroscience
  • Immunology
  • Ophthalmology

Background:

  • Glaucoma is a progressive optic nerve neurodegenerative disease.
  • Existing treatments focus on the primary cause, but neuroprotection remains challenging.
  • Autoimmunity is typically considered harmful, but recent findings suggest a protective role for T cells in CNS injury.

Purpose of the Study:

  • To investigate the potential of "protective autoimmunity" for neuroprotection in glaucoma.
  • To evaluate Cop-1, an FDA-approved drug, as an active vaccination strategy for optic nerve recovery.
  • To mitigate risks of inducing autoimmune disease while boosting beneficial immune responses.

Main Methods:

  • Developed an active vaccination strategy using Cop-1.
  • Cop-1 is a synthetic polymer designed to weakly cross-react with self-reactive T cells.
  • Tested the efficacy of Cop-1 vaccination in rat models of optic nerve crush and chronic glaucoma.

Main Results:

  • Vaccination with Cop-1 demonstrated significant neuroprotection in both optic nerve crush and chronic glaucoma rat models.
  • The study identified a T cell-based mechanism, "protective autoimmunity," that promotes optic nerve recovery.
  • Cop-1 vaccination effectively boosted this protective immune response without inducing autoimmune disease.

Conclusions:

  • Boosting T cell-mediated "protective autoimmunity" is a viable strategy for optic nerve neuroprotection.
  • Cop-1 vaccination shows promise as a therapeutic approach for glaucoma and other optic nerve injuries.
  • Further research is underway to translate this treatment into clinical therapy for patients.

Related Experiment Videos